Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High cardiovascular risk in Spanish workers.
Sánchez Chaparro MA, Calvo Bonacho E, González Quintela A, Cabrera M, Sáinz JC, Fernández-Labander C, Quevedo-Aguado L, Gelpi JA, Fernández Meseguer A, Brotons C, de Teresa E, González Santos P, Román García J; ICARIA (Ibermutuamur CArdiovascular RIsk Asessment) Study Group. Sánchez Chaparro MA, et al. Among authors: de teresa e. Nutr Metab Cardiovasc Dis. 2011 Apr;21(4):231-6. doi: 10.1016/j.numecd.2009.10.001. Epub 2010 Apr 10. Nutr Metab Cardiovasc Dis. 2011. PMID: 20382511
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Among authors: de teresa e. Am Heart J. 2007 May;153(5):881-8. doi: 10.1016/j.ahj.2007.02.029. Am Heart J. 2007. PMID: 17452168 Clinical Trial.
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Among authors: de teresa e. Kidney Int Suppl. 2008 Dec;(111):S60-3. doi: 10.1038/ki.2008.514. Kidney Int Suppl. 2008. PMID: 19034329 Free article. Clinical Trial.
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study.
Gupta M, Martineau P, Tran T, Després JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators. Gupta M, et al. Among authors: de teresa e. J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24. J Clin Pharmacol. 2012. PMID: 21610204 Clinical Trial.
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Martineau P, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Langer A; ACTFAST investigators. Martineau P, et al. Among authors: de teresa e. Atherosclerosis. 2007 Mar;191(1):135-46. doi: 10.1016/j.atherosclerosis.2006.03.019. Epub 2006 Apr 27. Atherosclerosis. 2007. PMID: 16643923 Clinical Trial.
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Gensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A; Achieve Cholesterol Targets Fast withAtorvastatin Stratified Titration Investigators. Gensini GF, et al. Among authors: de teresa e. Int J Cardiol. 2010 Jul 23;142(3):257-64. doi: 10.1016/j.ijcard.2008.12.213. Epub 2009 Feb 12. Int J Cardiol. 2010. PMID: 19217176 Clinical Trial.
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Blanco-Colio LM, Martín-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hérnandez G, Egido J; ACTFAST investigators. Blanco-Colio LM, et al. Among authors: de teresa e. Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):168-74. doi: 10.1161/01.ATV.0000250616.26308.d7. Epub 2006 Oct 19. Arterioscler Thromb Vasc Biol. 2007. PMID: 17053166 Free article. Clinical Trial.
Comparison of the new risk prediction model (HCM Risk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator.
Ruiz-Salas A, García-Pinilla JM, Cabrera-Bueno F, Fernández-Pastor J, Peña-Hernández J, Medina-Palomo C, Barrera-Cordero A, De Teresa E, Alzueta J. Ruiz-Salas A, et al. Among authors: de teresa e. Europace. 2016 May;18(5):773-7. doi: 10.1093/europace/euv079. Epub 2015 Apr 7. Europace. 2016. PMID: 25855675 Free article.
105 results